Products for Research Use Only

Etilevodopa

CAT: 0804-HY-116016-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-116016-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD) . Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine[1][2][3].
CAS Number
37178-37-3
Product Name Alternative
L-DOPA ethyl ester; Levodopa ethyl ester
UNSPSC
12352005
Hazard Statement
H302, H319
Target
Dopamine Receptor; Drug Metabolite
Type
Reference compound
Related Pathways
GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/etilevodopa.html
Purity
99.00
Solubility
H2O : 12 mg/mL (ultrasonic; warming)
Smiles
N[C@H](C(OCC)=O)CC1=CC=C(C(O)=C1)O
Molecular Formula
C11H15NO4
Molecular Weight
225.24
Precautions
H302, H319
References & Citations
[1]Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26 (6) :322-6.|[2]Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63 (2) :210-6.|[3]Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23 (1) . pii: E40.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3